Literature DB >> 8706727

Dipeptidyl-peptidase IV-beta, a novel form of cell-surface-expressed protein with dipeptidyl-peptidase IV activity.

E Jacotot1, C Callebaut, J Blanco, B Krust, K Neubert, A Barth, A G Hovanessian.   

Abstract

The T-cell activation antigen CD26, is a type II membrane glycoprotein with intrinsic dipeptidyl-peptidase IV (DPP IV) activity, characterized by its capacity to cleave off N-terminal dipeptides containing proline as the penultimate residue. Independent of its catalytic activity, CD26 has also been characterized as adenosine deaminase binding protein. By using CD26 negative human C8166 cells, here we describe the existence of another cell-surface protein which manifests CD26-like DPP IV activity. For convenience, this protein will be referred to as DPP IV-beta. Consistent with the cell-surface expression of DPP IV-beta, intact C8166 cells manifested a high level of DPP IV, whereas, they manifested poor activity against substrates of DPP II known to have an intracellular localization. A partially purified preparation of CD26 from human MOLT4 cells, and the DPP IV-beta expressed on intact cells were found to possess similar catalytic activity and pH optimum. In addition, cell-surface CD26 and DPP IV-beta on intact MOLT4 and C8166 cells, respectively, resisted digestion by proteolytic enzymes such as trypsin and proteinase K. However, adenosine deaminase activity was not detectable on the surface of C8166 cells in contrast to CD26 positive MOLT4 cells. In accord with this, 125I-labeled adenosine deaminase which binds CD26 was found not to bind DPP IV-beta. Gel-filtration experiments using 0.5% Triton X-100 extracts from C8166 and MOLT4 cells, revealed that the apparent molecular mass of DPP IV-beta is 82 kDa, whereas that of CD26 is 110 kDa as expected. Taken together, our results suggest that DPP IV-beta is a CD26-like protein which could be characterized by distinct properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706727     DOI: 10.1111/j.1432-1033.1996.0248u.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  8 in total

1.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

Authors:  D Marguet; L Baggio; T Kobayashi; A M Bernard; M Pierres; P F Nielsen; U Ribel; T Watanabe; D J Drucker; N Wagtmann
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Dipeptidyl-peptidase IV secreted by Aspergillus fumigatus, a fungus pathogenic to humans.

Authors:  A Beauvais; M Monod; J Wyniger; J P Debeaupuis; E Grouzmann; N Brakch; J Svab; A G Hovanessian; J P Latgé
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases.

Authors:  Shu Y Qi; Pierre J Riviere; Jerzy Trojnar; Jean-Louis Junien; Karen O Akinsanya
Journal:  Biochem J       Date:  2003-07-01       Impact factor: 3.857

4.  Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-α in transformed astrocytic cells.

Authors:  Eva Balaziova; Petr Busek; Jarmila Stremenova; Lucie Sromova; Evzen Krepela; Libuse Lizcova; Aleksi Sedo
Journal:  Mol Cell Biochem       Date:  2011-04-28       Impact factor: 3.396

5.  Catalytic properties and inhibition of proline-specific dipeptidyl peptidases II, IV and VII.

Authors:  Barbara Leiting; KellyAnn D Pryor; Joseph K Wu; Frank Marsilio; Reshma A Patel; Charles S Craik; Jonathan A Ellman; Richard T Cummings; Nancy A Thornberry
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

6.  Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.

Authors:  Bernard Krust; Diala El Khoury; Isabelle Nondier; Calaiselvy Soundaramourty; Ara G Hovanessian
Journal:  BMC Cancer       Date:  2011-08-03       Impact factor: 4.430

7.  Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia.

Authors:  B Bauvois; I De Meester; J Dumont; D Rouillard; H X Zhao; E Bosmans
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 8.  Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review.

Authors:  Srinivasan Vedantham; Anna-Kristina Kluever; Elisabeth Deindl
Journal:  Cells       Date:  2018-10-22       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.